Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Firefly Neuroscience, Inc. (AIFF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/17/2025: AIFF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -90.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.84M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 |
52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4802.33% |
Management Effectiveness
Return on Assets (TTM) -86.34% | Return on Equity (TTM) -860.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37724522 | Price to Sales(TTM) 279.43 |
Enterprise Value 37724522 | Price to Sales(TTM) 279.43 | ||
Enterprise Value to Revenue 271.4 | Enterprise Value to EBITDA - | Shares Outstanding 12861100 | Shares Floating 8202680 |
Shares Outstanding 12861100 | Shares Floating 8202680 | ||
Percent Insiders 40.48 | Percent Institutions 9.56 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Firefly Neuroscience, Inc.
Company Overview
History and Background
Firefly Neuroscience, Inc. (formerly known as Cognitive Research Corporation) was founded to develop advanced tools for brain health assessment using EEG technology. Their focus is on providing objective data to aid in the diagnosis and treatment of neurological and psychiatric conditions. Details regarding founding year and significant milestones are limited in publicly available resources.
Core Business Areas
- Neuroscience Solutions: Provides EEG-based assessment tools and services for diagnosing and monitoring neurological and psychiatric disorders.
- Clinical Trials: Partners with pharmaceutical companies and research institutions to enhance clinical trials through objective EEG data.
Leadership and Structure
Details of Firefly Neuroscience's leadership team and organizational structure are limited in publicly available sources.
Top Products and Market Share
Key Offerings
- Firefly Brain Network Analytics (BNA): Provides objective EEG data analysis to assist physicians in diagnosing and treating neurological and psychiatric conditions. Market share data is not readily available. Competitors include companies offering EEG analysis software and services, such as QEEG providers and companies developing AI-powered diagnostics.
Market Dynamics
Industry Overview
The neuroscience industry is experiencing growth driven by increased awareness of neurological and psychiatric disorders, technological advancements in brain imaging, and demand for objective diagnostic tools.
Positioning
Firefly Neuroscience aims to differentiate itself through advanced EEG analysis and data-driven insights to assist healthcare professionals in making more informed treatment decisions. They try to offer quantitative data where previously it was only qualitative.
Total Addressable Market (TAM)
The TAM for EEG-based diagnostic tools in neurology and psychiatry is estimated to be significant, potentially in the billions of dollars, driven by the high prevalence of neurological and psychiatric disorders. Firefly Neuroscience's positioning is within this market, targeting both clinical and research applications. Specific TAM value for Firefly is not found.
Upturn SWOT Analysis
Strengths
- Advanced EEG analysis technology
- Data-driven insights for clinical decision-making
- Potential for improved diagnostic accuracy
Weaknesses
- Limited publicly available financial information
- Relatively small market presence
- Requires physician adoption and integration into clinical workflows
Opportunities
- Partnerships with pharmaceutical companies and research institutions
- Expansion into new clinical applications
- Development of AI-powered diagnostic algorithms
Threats
- Competition from established EEG providers
- Technological advancements by competitors
- Regulatory hurdles and reimbursement challenges
Competitors and Market Share
Key Competitors
- Natus Medical Incorporated (NTUS)
- Compumedics Limited (CMP.AX)
- Electrical Geodesics, Inc. (EGI) - now part of Philips (PHG)
Competitive Landscape
Firefly Neuroscience faces competition from established EEG manufacturers and emerging AI-based diagnostic companies. Its competitive advantage lies in its specialized brain network analysis technology. Financial strength and market reach are potential disadvantages compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Unable to provide due to lack of financial data.
Future Projections: Future growth projections are not available from analyst estimates due to the company's private status.
Recent Initiatives: Unable to provide due to lack of publicly available information.
Summary
Firefly Neuroscience develops EEG analysis technology for neurological and psychiatric disorders, offering data-driven insights for clinicians. Limited public information, as a private company, hinders detailed analysis. Opportunities exist through partnerships and technological advancement, while competition and regulatory hurdles pose challenges. The company's success hinges on widespread adoption of its technology and securing a strong position in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website (limited information)
- Industry reports on the neuroscience market
- News articles and press releases
Disclaimers:
This analysis is based on limited publicly available information. Financial and operational data may not be complete or accurate. Market share data is estimated and may not reflect actual figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Firefly Neuroscience, Inc.
Exchange NASDAQ | Headquaters Kenmore, NY, United States | ||
IPO Launch date 2011-02-23 | CEO & Director Mr. Greg Lipschitz | ||
Sector Technology | Industry Software - Application | Full time employees 13 | Website https://fireflyneuro.com |
Full time employees 13 | Website https://fireflyneuro.com | ||
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.